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Abstract
Background: Lung cancer is a malignant carcinoma which has the highest morbidity and mortality in Chinese
population. Gefitinib, a tyrosine kinase (TK) inhibitor of epidermal growth factor receptor (EGFR), displays anti-tumor
activity. The present data regarding first-line treatment with single agent gefitinib against non-small-cell lung
cancer (NSCLC) in Chinese population are not sufficient.
Purpose: To assess the efficacy and toxicity of gefitinib in Chinese patients with advanced non-small-cell lung
cancer (NSCLC), a study of single agent treatment with gefitinib in Chinese patients was conducted.
Methods: 45 patients with advanced NSCLC were treated with gefitinib (250 mg daily) until the disease
progression or intolerable toxicity.
Results: Among the 45 patients, 15 patients achieved partial response (PR), 17 patients experienced stable disease
(SD), and 13 patients developed progression disease (PD). None of the patients achieved complete response (CR).
The tumor response rate and disease control rate was 33% and 71.1%, respectively. Symptom remission rate was
72.5%, and median remission time was 8 days. Median overall survival and median progression-free survival was
15.3 months and 6.0 months, respectively. The main induced toxicities by gefitinib were skin rash and diarrhea
(53.3% and 33.3%, respectively). The minor induced toxicities included dehydration and pruritus of skin (26.7% and
22.2%, respectively). In addition, hepatic toxicity and oral ulceration occurred in few patients (6.7% and 4.4%2,
respectively).
Conclusions: Single agent treatment with gefitinib is effective and well tolerated in Chinese patients with
advanced NSCLC.
Background
Lung cancer is a malignant carcinoma with high mor-
bidity and mortality in Chinese population. Non-small
cell lung cancer (NSCLC) accounts for approximately
80% of all lung cancers. The synthetical therapy has
been developed remarkably, however the efficacy on
locally advanced or metastatic NSCLC is still poor.
Recently, the molecular-targeted therapy with gefitinib
shows favorable performance. Gefitinib is a tyrosine
kinase (TK) inhibitor of epidermal growth factor recep-
tor (EGFR). It blocks signal pathways involved in prolif-
eration and survival of cancer cells [1], and displays
activity against malignant tumors. Two large randomised
phase II studies (IDEAL1 and 2) in patients with locally
advanced or metastatic NSCLC after failure of plati-
num-based chemotherapy showed a higher response
rate of gefitinib (12%-18%) [2,3]. Compared to docetaxel,
gefitinib showed superior progression-free survival
(PFS), objective response rate (ORR), better tolerability,
and similar quality of life (QOL) improvement rates in
pretreated NSCLC [4]. Gefitinib was also effective and
safe in Chinese patients with recurrent advanced
NSCLC [5].
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median survival time (MST) of 13.9 months and 1-year
survival rate of 55% in advanced NSCLC after first-line
single agent treatment with gefitinib[6]. Some other
groups also reported that first-line single agent treat-
ment with gefitinib may have better effect in patients
with advanced NSCLC than standard first-line che-
motherapy [7-10]. Gefitinib showed clinical benefits for
EGFR mutation NSCLC patients with extremely poor
performance status (PS)[11,12]. The large randomized
trial (IPASS research) which compared gefitinib with
carboplatin/paclitaxel in patients with advanced NSCLC
demonstrated superiority of gefitinib relative to carbo-
platin/paclitaxel in terms of PFS, ORR, tolerability, and
QOL improvement rates. However, the overall survival
(OS) and disease-related symptom improvement rates
were similar [13]. In 2009, Kim et al. demonstrated that
compared to pre-gefitinib eras, the survival of advanced
NSCLC patients was significantly improved in post-
gefitinib eras in Korea [14].
However, the present data regarding first-line treat-
ment with single agent gefitinib against NSCLC in
Chinese population are not sufficient. Here, we con-
ducted a study of single agent treatment with gefitinib
in 45 patients with advanced NSCLC in order to assess
its efficacy and toxicity in Chinese patients.
Materials and methods
Patients
45 patients with histologically or cytologically confirmed
stage IIIB or IV NSCLC received gefitinib as first-line
treatment between July 2006 and Oct 2008 at the First
Affiliated Hospital of Nanjing Medical University. All of
these patients were treated initially and had at least one
measurable focus according to standard Response Eva-
luation Criteria in Solid Tumors (RECIST) [15]. These
45 patients consisted of 19 males and 26 females with
median age around 61.8 years (range: 30-78). 17 patients
had smoking history. In terms of tumor histologic types,
the patients included 26 adenocarcinomas, 4 bronchio-
loalveolar carcinomas, 10 squamous cell carcinomas and
5 adenosquamous carcinomas. According to American
Joint Committee on Cancer (AJCC) staging manual, 14
patients were in stage IIIB and 31 patients in stage IV.
The Eastern Cooperative Oncology Group Performance
Status (ECOG-PS) value was less than 2 in 32 patients,
and 3 - 4 in 13 patients (Table 1). All patients provided
written informed consent before enrollment. This proto-
col was approved by the Institutional Review Boards of
the participating centers.
Therapy
Gefitinib (AstraZeneca Company) was administered
orally 250 mg daily, 28 days as a cycle. The treatment
was continued until disease progression or intolerable
toxicity.
Observation index
We conducted a thorough physical examination on each
patient to acquaint with the health status (PS method).
Blood routine, hepatic and renal function, electrocardio-
gram, PET/CT or CT were examined. These indexes
were reexamined regularly during the trial, and the
image examination was performed after the first one
cycle. After that, the image examination was conducted
once two cycles. The follow-up of patients by telephone
or outpatient service for 1 year was performed.
Evaluative standards
Tumor response was assessed as complete response
(CR), partial response (PR), stable disease (SD), or pro-
gression disease (PD) in accordance with the standard of
RECIST [15]. A CR was defined as the complete disap-
pearance of all clinically detectable tumors for at least
4 weeks. A PR was defined as an at least 30% decrease
in the sum of the longest diameters of the target lesions
for more than 4 weeks without new area of malignant
disease. PD indicated an at least 20% increase in the
sum of the longest diameter of the target lesions or a
new malignant lesion. Stable disease was defined as
insufficient shrinkage to qualify for PR and insufficient
increase to qualify for PD. An objective response rate
Table 1 Clinical material and efficacy of the 45 patients
Characters NO. CR, n
(%)
PR, n
(%)
SD, n
(%)
PD, n
(%)
Gender
Male 19 0 15.8(3) 36.8(7) 47.4(9)
Female 26 0 46.1(12) 38.5(10) 15.4(4)
Age(year)
< 70 35 0 34.3(12) 37.1(13) 28.6(10)
≥70 10 0 30.0(3) 40.0(4) 30.0(3)
Smoking status
Smokers 17 0 17.6(3) 41.2(7) 41.2(7)
Non-smokers 28 0 42.9(12) 35.7(10) 21.4(6)
Tumor histology
Adeno. 26 0 38.5(10) 42.3(11) 19.2(5)
BAC 4 0 75.0(3) 25.0(1) 0.0(0)
Squamous 10 0 10.0(1) 30.0(3) 60.0(6)
Adenosquamous 5 0 20.0(1) 40.0(2) 40.0(2)
Stage
IIIb 14 0 28.6(4) 50.0(7) 21.4(3)
IV 31 0 35.4(11) 32.3(10) 32.3(10)
Brain metastasis 4 0 75.0(3) 25.0(1) 0.0(0)
PS value
≤ 2 32 0 37.5(12) 37.5(12) 25.0(8)
3~4 13 0 23.0(3) 38.5(5) 38.5(5)
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and PR, while a disease control rate (DCR) indicated the
proportion of patients achieved CR, PR and SD. Progres-
sion-free survival (PFS) was measured from Day 1 of
treatment until the first objective or clinical sign of dis-
ease progression. Overall survival (OS) was measured
from Day 1 of treatment until the date of death. The
alteration of patients’ symptoms including appetite, fati-
gue, cough, dyspnea, hemoptysis and pain referencing to
Lung Cancer Symptom Scale (LCSS) [16] was observed.
Symptomatic remission was considered if the score over
25 points. Symptom remission time means the span
from initial administration to symptom remission.
Adverse effects including 5 degrees (0-IV) were evalu-
ated following the standard enacted by the World
Health Organization in 1981.
Statistical considerations
The data was analyzed by SPSS11.5. Intergroup compar-
ison was conducted by X2 checking. Survival analyses
were performed by Kaplan-Meier method. Survival
deviation was calculated by Log-Rank test. All P-values
were considered significant if P ≤ 0.05.
Results
Clinical efficacy
All of these patients were eligible. None of the patients
achieved CR. 15 patients (33.3%) achieved PR and 17
patients (37.8%) had stable disease (SD). 13 patients
(28.9%) developed progres s i v ed i s e a s e( P D ) .O R Ra n d
DCR was 33.3% and 71.1% respectively. Subset analysis
according to basic traits of the patients was shown in
Table 1. Table 2 showed that the efficacy of gefitinib
therapy correlated with gender, tumor histology (P <
0.05). However, other factors such as age, smoking sta-
tus, disease stage, and ECOG-PS didn’t correlate with
the efficacy of gefitinib therapy.
It is notable that there were 4 patients with brain
metastasis in this trial, including 3 cases of PR and 1
case of SD. Brain metastatic focuses disappeared in 2
patients of PR, and their primary tumor reduced. One
of them expressed headache palliative at the day 1. The
primary and metastatic tumors of one patient reduced
two weeks later.
Remission of symptoms
In this trial, except 5 patients whose PS = 0, 29 of the
other 40 patients (72.5%) achieved palliative symptoms
such as fatigue, cough, pain, etc. Remission time arranged
from 1 to 14 days, median remission time was 8 days.
Overall survival
MST of the 45 patients was 15.3 months by Oct 15, 2008,
(95% CI 11.22-19.38). OS arrange from 7.4 to 23 months,
and the patient who had the longest OS was still alive at
the most recent follow-up. The 1-year survival rate was
50%. The Kaplan-Meier survival curve was showed in
Figure 1. The MST of patients with adenocarcinoma
and non-adenocarcinoma was 17.1 months (95%CI
14.79-19.41) and 11.2 months (95%CI 8.67-13.73),
respectively. The MST of patients with adenocarcinoma
was remarkably longer than that of non-adenocarcinoma
(P = 0.0149) (Figure 2). Other factors such as gender,
smoking status, etc., had no obvious effects on survival
(Smokers indicated current or former smokers, and non-
smokers was defined as persons who had never smoked.). Table 2 Gradational analysis of ORR and DCR
Characters ORR(%) P value DCR(%) P value
Gender
Male 13.3 0.033 52.6 0.019
Female 40.0 84.6
Age(year)
< 70 34.3 1.000 71.4 1.000
≥70 30.0 70.0
Smoking status
Smokers 17.6 0.082 58.8 0.281
Nonsmokers 42.9 78.6
Tumor histology
Adeno. And BAC 43.3 0.044 83.3 0.027
Non-adeno. 13.3 46.7
Stage
IIIb 28.6 0.909 78.6 0.699
IV 35.5 67.7
PS value
≤ 2 37.5 0.561 75.5 0.589
3~4 23.1 61.5
Figure 1 Kaplan-Meier curve of OS for all patients.T h eM S Ti s
15.3 months. 1 year survival rate is 50%.
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The median PFS was 6.0 months, (95% CI 4.36-7.64).
Kaplan-Meier curve of PFS was showed in Figure 3.
Toxicity and adverse effects
As shown in Table 3, the most common toxicities of gefiti-
nib treatment were rash (53.3%) and diarrhea (33%). In
addition, 26.7% and 22.2% of the patients showed dehydra-
tion and pruritus of skin. 6.7% of the patients showed
Grade 2 or 3 hepatic toxicity. 4.4% of the patients (2 per-
sons) showed oral ulcer. No patients developed interstitial
lung disease (ILD). Most of the toxicity was grade 1 to 2,
and remitted after treatment. Grade 3 rash of one patient
was remitted by reducing the dose of gefitinib. The rela-
tionship between rash and OS is showed in Figure 4.
Discussion
Because of high morbidity and mortality, investigators
pay more attentions to the therapy of lung cancer in
recent years. Platinum-based combination chemotherapy
has been the standard first-line therapy for advanced
NSCLC. However, it brings about severe adverse effects
such as vomiting, renal toxicity, cytopenia, etc.. Recently,
molecular-targeted agents have been introduced in the
treatment of NSCLC. Gefitinib, a tyrosine kinase inhibi-
tor of EGFR, has been allowed to treat NSCLC clinically.
The second-line treatment with gefitinib has response
rate, survival benefit and safety not inferior to che-
motherapy. Two trials in patients who previously failed
platinum-based chemotherapy, IDEAL-1 and 2, revealed
a favorable ORR (12-18%), a DCR of 50%, and good tol-
erability of gefitinib treatment [2,3]. Gefitinib have been
suggested to have better efficacy in patients of females
or non-smokers, patients with adenocarcinoma (particu-
larly with bronchioloalveolar carcinoma), patients with
previous immune/endocrine therapy, and patients with a
PS of 0 or 1[2]. A trial about the treatment of NSCLC
patients from Asia with gefitinib resulted in an ORR
more than 25% and a DCR more than 60% [17].
Recently, Lee et al. [5] demonstrated that, as second-line
therapy, gefitinib has superior PFS, better tolerability,
Figure 2 Kaplan-Meier curve of OS for adenocarcinoma
patients (green) and non-adenocarcinoma (pink).
Adenocarcinoma was remarkably longer than that of non-
adenocarcinoma (P = 0.0149).
Figure 3 Kaplan-Meier curve of PFS. The median PFS was 6.0
months.
Table 3 Assessment of toxicity (case, %)
Toxicity Grade(WHO)
0 I II III IV
Rash 21(46.7) 19(42.2) 4(8.9) 1(2.2) 0(0)
Pruritus 35(77.8) 10(22.2) 0 0 0
Dry skin 33(73.3) 11(24.4) 1(2.2) 0 0
Diarrhea 30(66.7) 13(28.9) 2(4.4) 0 0
Oral ulcer 43(95.6) 2(4.4) 0 0 0
Nausea/vomit 37(82.2) 8(17.8) 0 0 0
Hepatic toxicity 42(93.3) 1(2.2) 2(4.4) 0 0
Interstitial lung Disease(ILD) 45(100.0) 0 0 0 0
Figure 4 Kaplan-Meier survival curve of patients with grade 0
to 3 acne-like rash.
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docetaxel.
Nowadays, more and more clinical investigations have
been carried out to evaluate the efficacy of gefitinib as
first-line treatment of advanced NSCLC. Niho et al.[6]
reported a response rate of 27% with gefitinib treatment
in 40 patients with advanced NSCLC. Yang et al.[18]
from Taiwan reported that first-line treatment with gefi-
tinib in 196 patients with NSCLC achieved an ORR of
42%, a DCR of 61%, and a 1-year survival rate of 47.5%.
A large phase III trial IPASS, which was designed to
compare gefitinib as first-line treatment of NSCLC
patients with standard chemotherapy, demonstrated
superiority of gefitinib in terms of 12-month rates of
PFS (24.9% vs. 6.7%, P < 0.05), ORR (43.0% vs. 32.2%,
P = 0.0001), and tolerability profile compared with car-
boplatin plus paclitaxel. Recently, Maemondo et al.[9]
reported that the gefitinib group had a significantly
longer median PFS (10.8 months vs. 5.4 months;
P < 0.001), as well as a higher response rate (73.7% vs.
30.7%, P < 0.001) than the standard chemotherapy
group. A study conducted in Japan also showed a longer
PFS in gefitinib group than the cisplatin plus docetaxel
group (9.2 months vs. 6.3 months, P < 0.0001) [10].
In our study of first-line treatment with gefitinib in
Chinese patients with advanced NSCLC, we obtained an
ORR of 33.3%, a DCR of 71.1%, a median PFS of 6.0
months, and a median OS of 15.3 months. These results
were compatible with the reports aforementioned.
T h eI P A S Ss t u d ys u g g e s t e dt h a tg e f i t i n i bw o u l db e
efficacious in first-line treatment of locally advanced or
metastatic NSCLC patients with adenocarcinoma who
have never or seldom smoked [13]. Consistent with this
result, we found that females and patients with adeno-
carcinoma (including bronchioloalveolar caicinoma)
were more sensitive to gefitinib. Although the response
rate of gefitinib in non-smokers seemed higher than
that in smokers, the result had no statistical significance
due to the small sample size. The OS of patients with
adenocarcinoma was longer than that of patients with
non-adenocarcinoma (17.1 months vs. 11.2 months,
P = 0.0149). However, other factors such as gender and
smoking status have no obvious correlation to OS. In
addition, we found that the OS of patients with rash
was longer than that of patients without rash, and a
longer OS was coupled with greater rash. Because there
were few cases with grade 2 or more serious rash, this
result needs to be verified further. Moreover, our study
showed favorable efficacy of gefitinib in patients with
brain metastasis.
Gefitinib is well tolerated in advanced NSCLC. The
common adverse effects of gefitinib were skin rash, diar-
rhea, anorexia, elevated aminotransferase lever, and
interstitial lung disease, etc [9-11,19]. Similarly, mild
toxicities including skin rash (53.3%), diarrhea (33%),
Grade 2 or 3 hepatic toxicity (6.7%), and oral ulcer
(4.4%) were observed in our study. No patients devel-
oped ILD. Since the tolerance of gefitinib in NSCLC is
better than chemotherapy, and gefitinib could provide
clinical benefits for patients with extremely poor PS
[11,12], it may be a better choice to treat patients who
can’t tolerate chemotherapy compared to best suppor-
tive care (BSC).
It has been recently reported that the sensitivity and
survival benefit of gefitinib treatment was higher in
NSCLC patients with EGFR mutations than the patients
without EGFR mutations [20-22]. Chinese patients of
lung cancer have a higher frequency of EGFR mutations
than American patients. As a result, Chinese patients
were much more sensitive to gefitinib than Americans
[23]. Besides mutations, gene copy number and poly-
morphism of EGFR were also related to the responsive-
ness of gefitinib in advanced NSCLC [24,25]. EGFR
mutations of NSCLC patients can be detected using
plasma and pleural effusion samples, which provides a
noinvasive method to predict the efficacy of gefitinib in
advanced NSCLC [26]. Detecting the mutations of
EGFR plays an important role in guiding the first-line
treatment with gefitinib in patients with advanced
NSCLC. Besides EGFR mutations, the favorable PFS
after gefitinib treatment was also associated with high
levels of serum surfactant protein D (SP-D) [27]. In
future studies, we will investigate the molecules which
affect and (or) can be used to predict the efficacy of
gefitinib in NSCLC.
Conclusions
Single agent treatment with gefitinib is effective in
patients with advanced NSCLC, and well tolerated
in Chinese patients. Gefitinib could be used as first-
line treatment for specific subgroups of NSCLC
such as females, non-smokers, and patients with
adenocarcinoma.
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